Keith Katkin

This profile gathers the share dealings of Keith Katkin across 4 companies, led by Syndax Pharmaceuticals Inc, Emergent BioSolutions Inc. and Eledon Pharmaceuticals, Inc. The record holds 15 filings, for trades running from 19 May 2021 to 4 February 2026.

In open-market terms, that means 1 purchase worth €81k on one side and 1 sale worth €44k on the other. Taken together, the purchases exceed the sales by €37k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 10 share grants and 3 option exercises.

On 6 February 2026 came the latest disclosure, a share grant in Syndax Pharmaceuticals Inc. The last purchase on record was published on 19 May 2025, which is 517 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.